Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02197091 · ClinicalTrials.gov registry record

Communication Effectiveness in Cancer Treatment

A clinical trial of Malignant Neoplasm, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
100
Enrollment target
1
Study location

NCT02197091: Completed study of Malignant Neoplasm, sponsored by Wake Forest University Health Sciences.

NCT02197091 is a study of Malignant Neoplasm that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 100 participants, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02197091, a study of Malignant Neoplasm, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

This pilot research trial studies communication effectiveness in cancer treatment. Studying how well patients and their doctors communicate about the treatment being given for cancer may help improve the decisions that patients and physicians make together.

Primary Outcome

The precision of agreement between patient's and doctor's responses about the intent of therapy will be assessed. The level of agreement between the questions as answered by the patient on the Prognosis Instrument and by the doctor on the Doctor Questionnaire will be assessed. Agreement will be measured as either "yes" (meaning the doctor and patient responses match exactly) or "no" (any other combination, if both doctor and patient responded). The primary measure of agreement will be the Kappa

Conditions Studied

Interventions

  • OTHER medical chart review
  • OTHER questionnaire administration

Study Locations (1)

North Carolina

  • Comprehensive Cancer Center of Wake Forest University - Winston-Salem

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2014-07
Est. Completion 2016-03
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT02197091 record still lists

NCT02197091 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which medical chart review is the first listed.

NCT02197091 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02197091 about?

NCT02197091 is a clinical study titled "Communication Effectiveness in Cancer Treatment". This pilot research trial studies communication effectiveness in cancer treatment. Studying how well patients and their doctors communicate about the treatment being given for cancer may help improve the decisions that patients and physicians make together.

What is the current status of trial NCT02197091?

This trial is currently completed. The enrollment target is 100 participants. The study started on 2014-07. Estimated completion is 2016-03.

What conditions does trial NCT02197091 study?

This clinical trial studies the following conditions: Malignant Neoplasm.

What interventions are being tested in trial NCT02197091?

The interventions under investigation include: medical chart review (OTHER), questionnaire administration (OTHER).

Who is sponsoring clinical trial NCT02197091?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02197091 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02197091's enrollment target sits among peer trials

100 33rd of 59 higher than 25 of 59 other Malignant Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02197091, the US trial registry maintained by the National Library of Medicine. NCT02197091 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.